ReviewCNS drugs2018
Treatment Strategies for Dravet Syndrome.
Review in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Trial
- Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach.Epilepsia open · 2026Article
- A multielectrode array reveals therapeutic potential of translocator protein ligands in a zebrafish model of Dravet syndrome.The Journal of pharmacology and experimental therapeutics · 2025Article
- Spotlight on mechanism of sudden unexpected death in epilepsy in Dravet syndrome.Translational psychiatry · 2025Review
- Metabolic aspects of genetic ion channel epilepsies.Journal of neurochemistry · 2024Review
- Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.Epilepsia open · 2024Review
- Channelopathies in epilepsy: an overview of clinical presentations, pathogenic mechanisms, and therapeutic insights.Journal of neurology · 2024Review
- Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy.BMC pediatrics · 2023Article
- The Promising Epigenetic Regulators for Refractory Epilepsy: An Adventurous Road Ahead.Neuromolecular medicine · 2023Review
- Genetic Diagnosis Impacts Medical Management for Pediatric Epilepsies.Pediatric neurology · 2023Article
- Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.CNS drugs · 2022Review
- Article
- A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway.Epilepsia open · 2020Article
- Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review.Frontiers in pharmacology · 2020Review
- A Novel Kv7.3 Variant in the Voltage-Sensing SFrontiers in physiology · 2020Article
- Stiripentol: A Review in Dravet Syndrome.Drugs · 2019Review
- Treatment of Seizures Associated with Lennox-Gastaut and Dravet Syndromes: A Focus on Cannabidiol Oral Solution.P & T : a peer-reviewed journal for formulary management · 2019Article
- Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome.Brain communications · 2019Article
- Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.Current treatment options in neurology · 2018Review
Corrections and comments
- Erratum issuedCorrection to: Treatment Strategies for Dravet Syndrome.2018 · Abstract corrected
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomic dysfunction). Complete seizure control is generally not achievable with current therapies, and the goals of treatment are to balance reduction of seizure burden with adverse effects of therapies. Treatment of co-morbidities must also be addressed, as they have a significant impact on the quality of life of patients with DS. Seizures are typically worsened with sodium-channel agents. Accepted first-line agents include clobazam and valproic acid, although these rarely provide adequate seizure control. Benefit has also been noted with stiripentol, topiramate, levetiracetam, the ketogenic diet and vagal nerve stimulation. Several agents presently in development, specifically fenfluramine and cannabidiol, have shown efficacy in clinical trials. Status epilepticus is a recurring problem for patients with DS, particularly in their early childhood years. All patients should be prescribed a home rescue therapy (usually a benzodiazepine) but should also have a written seizure action plan that outlines when rescue should be given and further steps to take in the local hospital if the seizure persists despite home rescue therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.